title: Long-term consequences of perinatal fatty acid amino hydrolase inhibition.
abstract: OBJECTIVE
  Fatty acid amide hydrolase inhibitors show promise as a treatment for anxiety, depression and pain. Here we investigated whether perinatal exposure to URB597, a fatty acid amide hydrolase inhibitor, alters brain development and affects behaviour in adult mice.
  
  
  METHODS
  Mouse dams were treated daily from gestational day 10.5 to 16.5 with 1, 3 or 10 mg kg−1 URB597. MS was used to measure a panel of endocannabinoids and related lipid compounds and brain development was assessed at embryonic day 16.5. Separate cohorts of mouse dams were treated with 10 mg kg−1 URB597, from gestational day 10.5 to postnatal day 7, and the adult offspring were assessed with a battery of behavioural tests.
  
  
  RESULTS
  Perinatal URB597 exposure elevated anandamide and related N-acyl amides. URB597 did not induce signs of toxicity or affect dam weight gain, neurogenesis or axonal development at embryonic day 16.5. It did lead to subtle behavioural deficits in adult offspring, manifested by reduced cocaine-conditioned preference, increased depressive behaviours and impaired working memory. Anxiety levels, motor function and sensory-motor gating were not significantly altered.
  
  
  CONCLUSIONS
  Taken together, the present results highlight how exposure to elevated levels of anandamide and related N-acyl amides during brain development can lead to subtle alterations in behaviour in adulthood.
  
  
  BACKGROUND
  This article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-6
authors.forename: Chia-Shan
authors.initials: CS
authors.lastname: Wu
authors.forename: Daniel
authors.initials: D
authors.lastname: Morgan
authors.forename: Chris P
authors.initials: CP
authors.lastname: Jew
authors.forename: Chris
authors.initials: C
authors.lastname: Haskins
authors.forename: Mary-Jeanette
authors.initials: MJ
authors.lastname: Andrews
authors.forename: Emma
authors.initials: E
authors.lastname: Leishman
authors.forename: Corinne M
authors.initials: CM
authors.lastname: Spencer
authors.forename: Traci
authors.initials: T
authors.lastname: Czyzyk
authors.forename: Heather
authors.initials: H
authors.lastname: Bradshaw
authors.forename: Ken
authors.initials: K
authors.lastname: Mackie
authors.forename: Hui-Chen
authors.initials: HC
authors.lastname: Lu
mesh_terms: D000581:Amidohydrolases / Q000037:antagonists & inhibitors*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001549:Benzamides / Q000494:pharmacology; D002219:Carbamates / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D051379:Mice; D008813:Mice, Inbred ICR; D011247:Pregnancy; D000099252:Fatty Acid Amide Hydrolases
chemical_list: D000581:Amidohydrolases; D001549:Benzamides; D002219:Carbamates; D004791:Enzyme Inhibitors; D000099252:Fatty Acid Amide Hydrolases; C500528:cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester
references.citation: BMC Neurosci. 2010 Mar 26;11:44
references.pmid: 20346144
references.citation: Eur J Neurosci. 2010 Sep;32(5):693-706
references.pmid: 21050275
references.citation: Addict Biol. 2007 Sep;12(3-4):485-95
references.pmid: 17578508
references.citation: Pharmacol Biochem Behav. 1998 Nov;61(3):229-38
references.pmid: 9768557
references.citation: Eur Arch Psychiatry Clin Neurosci. 2009 Oct;259(7):395-412
references.pmid: 19568685
references.citation: J Neurosci. 2005 Jan 5;25(1):247-51
references.pmid: 15634788
references.citation: Nat Protoc. 2006;1(1):7-12
references.pmid: 17406205
references.citation: Br J Pharmacol. 2010 Aug;160(7):1573-6
references.pmid: 20649560
references.citation: Neuropsychopharmacology. 2007 Mar;32(3):646-57
references.pmid: 16738542
references.citation: Neurotoxicol Teratol. 1995 Jul-Aug;17(4):479-87
references.pmid: 7565494
references.citation: BMC Biochem. 2009 May 21;10:14
references.pmid: 19460156
references.citation: Eur Arch Psychiatry Clin Neurosci. 2009 Oct;259(7):371-82
references.pmid: 19588184
references.citation: Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9371-6
references.pmid: 11470906
references.citation: Biol Psychiatry. 2007 Nov 15;62(10):1103-10
references.pmid: 17511970
references.citation: Neuroendocrinology. 2005;81(4):273-82
references.pmid: 16131814
references.citation: Development. 2008 Dec;135(23):3911-21
references.pmid: 18997113
references.citation: Neuropsychopharmacology. 2005 Nov;30(11):2046-57
references.pmid: 15870833
references.citation: Nature. 1999 Jul 29;400(6743):452-7
references.pmid: 10440374
references.citation: J Neurosci. 2012 Nov 21;32(47):16651-65
references.pmid: 23175820
references.citation: Nat Med. 2008 Sep;14(9):923-30
references.pmid: 18776886
references.citation: Pain. 2004 Jun;109(3):319-327
references.pmid: 15157693
references.citation: Neuroscience. 2001;105(1):7-17
references.pmid: 11483296
references.citation: Nicotine Tob Res. 2004 Feb;6(1):145-58
references.pmid: 14982698
references.citation: Horm Behav. 1997 Jun;31(3):197-211
references.pmid: 9213134
references.citation: Am J Physiol Regul Integr Comp Physiol. 2006 Aug;291(2):R349-58
references.pmid: 16556899
references.citation: Biochemistry. 2007 Nov 13;46(45):13019-30
references.pmid: 17949010
references.citation: Trends Pharmacol Sci. 2007 Feb;28(2):83-92
references.pmid: 17222464
references.citation: FASEB J. 2005 Oct;19(12):1704-6
references.pmid: 16037095
references.citation: Dev Disabil Res Rev. 2011;17(2):71-84
references.pmid: 23362027
references.citation: Biol Pharm Bull. 1999 Apr;22(4):366-70
references.pmid: 10328555
references.citation: Nat Neurosci. 2002 Sep;5(9):868-73
references.pmid: 12195431
references.citation: J Psychopharmacol. 2012 Jan;26(1):164-76
references.pmid: 21669929
references.citation: Psychopharmacology (Berl). 1997 Jul;132(2):169-80
references.pmid: 9266614
references.citation: Annu Rev Pharmacol Toxicol. 2006;46:101-22
references.pmid: 16402900
references.citation: Mol Psychiatry. 2002;7(10):1039-53
references.pmid: 12476318
references.citation: Bioorg Med Chem Lett. 2009 May 15;19(10):2865-9
references.pmid: 19386497
references.citation: Future Neurol. 2011 Jul 1;6(4):459-480
references.pmid: 22229018
references.citation: Cell Metab. 2006 Mar;3(3):167-75
references.pmid: 16517404
references.citation: Trends Pharmacol Sci. 2011 Sep;32(9):551-61
references.pmid: 21757242
references.citation: Neuropsychopharmacology. 2006 Jan;31(1):58-69
references.pmid: 15920503
references.citation: Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S84-90
references.pmid: 18394789
references.citation: Br J Pharmacol. 2013 Dec;170(8):1607-51
references.pmid: 24528239
references.citation: Psychopharmacology (Berl). 2005 Jan;177(3):245-55
references.pmid: 15609067
references.citation: Science. 2011 Nov 11;334(6057):809-13
references.pmid: 22021672
references.citation: Expert Opin Drug Discov. 2009 Jul;4(7):763-784
references.pmid: 20544003
references.citation: Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8760-5
references.pmid: 18562289
references.citation: Pharmacol Res. 2011 Sep;64(3):226-34
references.pmid: 21600985
references.citation: Physiol Rev. 2009 Jan;89(1):309-80
references.pmid: 19126760
references.citation: Eur Arch Psychiatry Clin Neurosci. 2009 Oct;259(7):383-93
references.pmid: 19572160
references.citation: J Med Chem. 1997 Feb 28;40(5):659-67
references.pmid: 9057852
references.citation: Neurotoxicol Teratol. 2003 Jul-Aug;25(4):427-36
references.pmid: 12798960
references.citation: CNS Drug Rev. 2006 Spring;12(1):21-38
references.pmid: 16834756
references.citation: Hum Mol Genet. 2000 May 1;9(8):1145-59
references.pmid: 10767339
references.citation: Mol Pharmacol. 2005 Jan;67(1):15-9
references.pmid: 15465922
references.citation: Br J Pharmacol. 2010 Aug;160(7):1577-9
references.pmid: 20649561
references.citation: AAPS J. 2006 Apr 28;8(2):E298-306
references.pmid: 16796380
references.citation: Physiol Rev. 2003 Jul;83(3):1017-66
references.pmid: 12843414
references.citation: Mol Pharmacol. 2006 Sep;70(3):786-92
references.pmid: 16772520
references.citation: Biochem Biophys Res Commun. 2006 Sep 1;347(3):827-32
references.pmid: 16844083
references.citation: Nat Rev Neurosci. 2003 Nov;4(11):873-84
references.pmid: 14595399
references.citation: Pharmacology. 2012;90(1-2):19-39
references.pmid: 22776780
references.citation: Pharmacol Res. 2013 Jan;67(1):94-109
references.pmid: 23127915
references.citation: Psychopharmacology (Berl). 2008 Jul;198(4):529-37
references.pmid: 18452035
references.citation: J Pharmacol Exp Ther. 2004 Nov;311(2):441-8
references.pmid: 15229230
references.citation: Pharmacol Res. 2007 Nov;56(5):360-6
references.pmid: 17945507
references.citation: Psychopharmacology (Berl). 2011 Mar;214(1):5-15
references.pmid: 20556598
references.citation: Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20270-5
references.pmid: 19918051
references.citation: Addict Sci Clin Pract. 2011 Jul;6(1):57-70
references.pmid: 22003423
references.citation: Psychopharmacology (Berl). 2007 May;192(1):61-70
references.pmid: 17279376
references.citation: Biochemistry. 2006 Aug 1;45(30):9007-15
references.pmid: 16866345